Document converted with www.koolwire.com

CURRICULUM VITAE
RESUMIDO
Nombre Completo:
Fecha de Nacimiento
Posición Actual
Coordinador de Infectología del Instituto Sacre Cour Consultor permanente de Infectología del Hospital Municipal de Chivilcoy. Coordinador científico de ClinicalREC (www.clinicalrec.com.ar) Dirección Profesional
Teléfono : (+5411)4854-4027
Móvil : (+54911)4400-7468
e-mail1: djcurcio@gmail.com
e-mail2: djcurcio@clinicalrec.com
Dirección Particular
Teléfono: (+54-11)4834-6647
e-mail: djcurcio@gmail.com
Formación Médica
Títulos Obtenidos
Secretaría de Salud PúblicaGCA de Buenos Aires Experiencia Laboral en Hospitales
Hospital Velez Sarsfield (Residente de Medicina Interna) Hospital Muñiz (Residente de Ciencias Microbiológicas) Hospital Muñiz (Jefe de Residentes de Ciencias Microbiológicas) Hospital Bocalandro (Infectólogo de Planta) Sanatorio Guemes (Coordinador de Infectología) Sanatorio San José (Coordinador de Infectología) Sanatorio Itoiz (Miembro del Equipo de Ensayos Clínicos) 2004 al presente Hospital de Chivilcoy (Consultor de Infectología) 2004 al presente Instituto Sacre Cour (Coordinador de Infectología) Experiencia con Antibióticos
-Asesorías
-Adviser para antibióticos (BMS Argentina) -1999/2001- -Adviser para antibióticos (Bagó Argentina) -1999/2008- -Miembro del Latin-American Advisory Board para Tygacil® -Adviser para antibióticos (Wyeth Argentina) -2004, al presente- -Adviser para antibióticos (Wyeth Colombia) -2004, al presente- -Adviser para antibióticos (Wyeth Chile) -2004, al presente- -Adviser para antibióticos (Wyeth Ecuador) -2005, al presente- -Adviser para antibióticos (Bagó Bolivia) -2008, al presente- -Miembro del APEX Program (Antibiotic Practices and Executions for Excellence) -2008, al -Miembro del Latin American Antibiotic Use in Intensive Care Unit Group (ATB-ICU) -2008, al presente- Publicaciones Internacionales
Bantar C., Bevestrello L., Curcio D., et al. Acute community-acquired pneumonia in adults:
guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur). J Chemother. 2002 Dec;14(6):635-6.
Bantar C., Bevestrello L., Curcio D., et al. Acute community-acquired pneumonia in adults:
guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur). J Chemother, Dec 2002 14(6):Suppl 4, 1-22 Jasovich A., Bantar C., Curcio D. et al. Efficacy of Amoxicillin-Sulbactam, Given Twice-a-Day, for
the Treatment of Community Acquired Pneumonia. A Clinical Trial Based on a Pharmacodynamic Jasovich A., Curcio D., Caso Nuñez H., et al. Impact of the Infectious Disease Team on the
Rationale for Antibiotic Usage: an Expeditious Intervention Strategy Avoiding the Physician Freedom Limitation. J Chemother 2003;15(4):409-11 Curcio D, Belloni R Strategic alliance between the infectious diseases specialist and intensive care
unit physician for change in antibiotic use J Chemother. 2005 Feb;17(1):74-6.
Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, Loh E, Roseç G.
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis. 2005 Sep;9(5):251-61.
Curcio D., Istúriz R. Tigecycline, the first glycylcycline. Rev Pan Infectología 2006;8(3):35-42
Curcio D., Fernández F. Tigecycline Use in Critically Ill Older Patients: Case Reports and Critical
Analysis J Am Geriatrics Soc 2007;55(2):312-3 Curcio D., Fernández F. What is the best denominator with which to measure antibiotic
Clin Microbiol Infect. 2007 May;13(5):553. Curcio D, Fernandez F, Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Sader HS.
Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view.
J Clin Microbiol. 2007 Jun;45(6):2095.
Curcio D, Fernandez F. Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective. J
Antimicrob Chemother. 2007 Aug;60(2):449-50.
Curcio D., Fernández F., Galas M., Duret F. A combination of mathematical and statistical models
to distinguish between "Susceptible" and "Resistant" clusters in the susceptibility disk diffusion method. Experien publice with Acinetobacter spp. and tigecycline. J Chemother. 2007 Curcio D., Fernández F.,Duret F. Initial Use of Tigecycline in Argentina. Rev Chilena Infectol. 2007
Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective J Clin
Curcio D. Fernández F. Tigecycline for Acinetobacter baumannii Infections : Other Considerations.
Clin Infect Dis. 2008 Jun 1;46(11):1797-8.
Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study.Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008 Jun 1;46(11):1683-93.
Curcio D. Tigecycline for treating bloodstream infections: a critical analysis of the available
evidence. Diagn Microbiol Infect Dis. 2008 Jul;61(3):358-9; Curcio D., Fernández F., Cané A., et al. Indications of a new antibiotic in clinical practice : results
of the tigecycline initial use registry. Braz J Infect Dis 2008;12(3):198-201.
Curcio D. Fernández F . Comment on: Effect of different Mueller-Hinton agars on tigecycline disc
diffusion susceptibility for Acinetobacter spp. J Antimicrob Chemother. 2008 Nov;62(5):1166-7.
Curcio D. Comment: Tigecycline treatment of Acinetobacter infections: a case series Ann
Pharmacother. 2008 Nov;42(11):1717-8.
Rossi F, García P, Ronzon B, Curcio D, Dowzicky MJ. Rates of antimicrobial resistance in latin
america (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics.
Braz J Infect Dis. 2008 Oct;12(5):405-415.
Curcio D., Fernández F., Vergara J . et al. Late onset ventilator-associated pneumonia due to
multidrug-resistant Acinetobacter spp: experience with tigecycline. J Chemother. 2009 García P, Porte L, Curcio D. In vitro evaluation of tygecicline: Influence of Mueller-Hinton agar
difusión methods and validation of E-test ® for Acinetobacter baumannii. Rev Chil Infect Campos M, Curcio D, Seas C, et al. Tigecycline as effective as vancomycin plus aztreonam in the
treatment of complicated skin and skin structure infections: Experience in Latin America. Rev Chil García P., Juliet C., Fernández A, San Martín M., Cifuentes M., Porte L., Braun S., Castillo L., Vechiola M., Tapia C., Sakurada A., Chanqueo L., Lam M., Espinoza M. y Curcio D.Estudio
multicéntrico de la vigilancia de la susceptibilidad in vitro a tigeciclina en Santiago de Chile. Rev Bantar C., Curcio D., Leal A., et al. Comparative in vitro activity of tigecycline against bacteria
recovered from clinical specimens in Latin America. J Chemother. 2009 Apr;21(2):144-52.
Curcio D., Barcelona L., Cornistein W., et al. Current Rational to Prescribe Tigecycline: Critical
Analysis of the Evidence and Usage Algorithms by an Argentinean Experts Panel. Clin Med Ther Curcio D. Tigecycline in the treatment of community-acquired pneumonia. Clinical Medicine:
Curcio D. Off-label use of antibiotics in hospitalized patients : Focus on tigecycline. J Antimicrob
Curcio D, Alí A, Duarte A, et al. Prescription of antibiotics in intensive care units in Latin America:
an observational study. J Chemother. 2009 Nov;21(5):527-34.
Curcio D.; Nacinovich F.; Chistin M et al. Tygecicline for the treatment of multiresistant Gram
negative rods causing mediastinitis: case reports and critic analysis. Infectio 2009,13:58-63. Curcio D. Antibiotic stewardship: The "real world" when the resources are limited. Infect Control
Curcio D., Castagnino J., Vazquez W., Vergara G., Curiale A. Tigecycline in the Treatment of
Ventilator-Associated Pneumonia: Experience from a Registry. Infez Med. 2010 Mar;18(1):27-34.
Ultimas Conferencias Internacionales (solo 2009 y 2010)
Latinoamérica
-Antibiotic Practices and Executions for Excellence; Brazil (several cities). Abril 2009.
-Tygacil Stand Alone Program; Cartagena, Colombia. Abril 2009.
-Congreso Colombiano de Infectología; Cali; Colombia. Mayo 2009.
-Curso Internacional Emergencias Médicas y Paciente Crítico; Santiago, Chile. Mayo 2009.
-Congreso Ecuatoriano de Infectología; Guayaquil; Ecuador. Agosto 2009.
-Congreso Colombiano de Cirugía; Medellín, Colombia. Agosto 2009 -Tygacil Stand Alone Program; Santiago, Chile. Agosto 2009.
-Congreso Colombiano de Neumonología; Bogotá; Colombia. Octubre 2009.
-Congreso Venezolano de Infectología; Maracaibo; Venezuela. Octubre 2009.
-Antibiotic Practices and Executions for Excellence; México (several cities). Febrero 2010.
-Sharing Tigecycline Experience Program; San José; Costa Rica. Marzo 2010.
-Antibiotic Practices and Executions for Excellence; Brazil (varias ciudades). Mayo 2010.
-Antibiotic Optimization Program; Bolivia (varias ciudades). Junio 2010.
Resto del Mundo
-7th International Symposium on Antimicrobial Agents and Resistance; Bangkok, Thailand. Marzo -29th International Symposium on Intensive Care and Emergency Medicine; Brussels, Belgium. -Tigeciclina: Experiencia Clínica; Madrid, Spain. Marzo 2009.
-Sharing Tygacil Experience Programme; Panamá City. Panamá. Abrill 2009.
-19yh European Society of Clinical Microbiology and Infectious Diseases; Helsinki, Finland. Mayo -Antibiotic Practices and Executions for Excellence; Lisbon, Portugal. Mayo 2009.
-Your Leadership Counts; Texas, US. Junio 2009.
-14th International Congress on Infectious Diseases; Miami; USA. Marzo 2010 Ensayos Clínicos
Clinical Efficacy and Safety of Amoxicillin / Sulbactam (875/125 mg) in two Doses Day for Treatment Community-Acquired Pneumonia (sub-investigador) Linezolid vs. Vancomycin / Oxacilin / Dicloxacilin in the treatment of Catheter Related Gram – Positive Bloodstream Infections (sub-investigador).
A Multicenter, Randomized, Double-Blind Comparison of the Efficay and Safety of Tigecycline with those of Vancomycin with Aztreonam to Treat Complicated Skin and Skin Structure Infections in Hospitalized Patients. Protocol 300 (Investigador Principal).
A Multicenter, Randomized, Double-Blind Comparison of the Efficay and Safety of Tigecycline with those of Imipenem to Treat Complicated Intra-abdominal Infections in Hospitalized Patients A Multicenter, Randomized, Open-Label Comparison of the Efficay and Safety of Tigecycline with those of Ceftriaxone-Metronidazol to Treat Complicated Intra-abdominal Infections in Hospitalized Patients Protocol 400 (Investigador Principal) A Multicenter, Randomized, Open-Label, Comparative, Study to evaluate the efficay and safetyof levofloxacin in the treatment of children who have recurrent and/or persistent acute otitis media A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of IntravenousTelavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus Protocol 0019 (Investigador A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of IntravenousTelavancin Versus Vancomycin-Aztreonam for Treatment of Skin and Skin Structure Infections with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus Protocol 0018 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Safety, and Clinical Equivalence of a Generic Mupirocin Calcium Cream 2% vs Bactroban® Cream 2% in the Treatment of Secondarily Infected Traumatic Skin Lesions Due to Strains of Staphylococcus aureus or Streptococcus pyogenes. (Investigador Principal).
A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection. (Investigador Principal).
A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia. A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Topical Retapamulin Ointment, 1% versus Placebo in Subjects with Secondarily-Infected Traumatic Lesions (Investigador Principal)

Source: http://ammctionline.com.mx/reunionammcti2010.com/images/programa/Curcio_CV_spanish.pdf